Mesenteric approach for borderline resectable pancreatic head cancer: a 13-Year retrospective cohort study
Author:
Open Access
- 29 August 2025
- journal article
- research article
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 410 (1) , 1-10
Abstract
Objective To evaluate the value of mesenteric approach for borderline resectable pancreatic head cancer(BRPHC). Methods According to the inclusion and exclusion criteria, the data of 203 patients with borderline resectable pancreatic head cancer(BRPHC) who underwent radical pancreatoduodenectomy in our center from January 2011 to December 2023 were retrospectively analyzed. After detecting the superior mesenteric artery in infracolic compartment to judge that there was vascular invasion but it met the borderline resection criteria, the blood supply was cut off first, then the tissues and organs were resected. And the invaded vessels were resected and reconstructed or replaced, then conventional anastomosis was performed. All patients were divided into mesenteric approach group and conventional approach group according to the operation method. The outcome measures were operation completion, perioperative conditions and overall prognosis. The follow-up time was up to February 2025. Results All 203 patients successfully completed the operation without perioperative death, and confirmed as pancreatic ductal adenocarcinoma by pathological examination. Overall and grouped prognosis: The overall survival rates and disease-free survival rates of 1-, 2-, and 5-year were 51.9%, 25.0%, 8.5% and 28.4%, 12.9%, 3.9% (Fig. 1). The 1-, 2-, and 5-year survival rates of patients in two groups were 62.1%, 40.3%, 21.7% and 44.1%, 14.7%, 1.8% (P = 0.000, X2 = 20.927) (Fig. 2A); The 1-, 2-, and 5-year disease-free survival rates in two groups were 44.9%, 24.5%, 8.2% and 20.8%, 7.5%, 1.9% (P = 0.006, X2 = 7.457) (Fig. 2B). Conclusion The mesenteric approach in infracolic compartment can improve the prognosis of patients with borderline resectable pancreatic head cancer, prolong the postoperative survival time of patients, and reduce the recurrence.Keywords
All Related Versions
This publication has 26 references indexed in Scilit:
- Surgery for Borderline Resectable Pancreatic Ductal AdenocarcinomaSurgical Clinics of North America, 2024
- Neoadjuvant chemotherapy is associated with improved disease‐free survival in pancreatic cancer patients undergoing pancreaticoduodenectomy with vascular resectionJournal of Surgical Oncology, 2024
- Five-year recurrence/survival after pancreatoduodenectomy for pancreatic adenocarcinoma: does pre-existing diabetes matter? Results from the Recurrence After Whipple's (RAW) studyHPB, 2024
- Comparing oncologic and surgical outcomes of robotic and laparoscopic pancreatoduodenectomy in patients with pancreatic cancer: a propensity-matched analysisSurgical Endoscopy, 2024
- A Multi-Institutional Safety and Feasibility Study Exploring the Use of Hydrogel to Create Spatial Separation between the Pancreas and Duodenum in Patients with Pancreatic CancerPractical Radiation Oncology, 2023
- Intraoperative electrochemotherapy of the posterior resection surface after pancreaticoduodenectomy: Preliminary results of a hybrid approach treatment of pancreatic cancerBioelectrochemistry, 2023
- Quality of life after pancreatoduodenectomy: Is the outcome predetermined by the diagnosis?Journal of Surgical Oncology, 2023
- Isolated pancreatectomy using mesenteric approachJournal of Hepato-Biliary-Pancreatic Sciences, 2021
- Recurrence patterns of pancreatic cancer after pancreatoduodenectomy: systematic review and a single-centre retrospective studyHPB, 2020
- Mesenteric approach during pancreaticoduodenectomy for pancreatic ductal adenocarcinomaAnnals of Gastroenterological Surgery, 2017